Document is current
Any future updates will be listed below
-
Authors
Goddard, Jack
Castle, Jemma
Southworth, Emily
Fletcher, Anya
Crosier, Stephen
Martin-Guerrero, Idoia
García-Ariza, Miguel
Navajas, Aurora
Masliah-Planchon, Julien
Bourdeaut, Franck
Dufour, Christelle
Ayrault, Olivier
Goschzik, Tobias
Pietsch, Torsten
Sill, Martin
Pfister, Stefan M.
Rutkowski, Stefan
Richardson, Stacey
Hill, Rebecca M.
Williamson, Daniel
Bailey, Simon
Schwalbe, Edward C.
Clifford, Steven C. http://orcid.org/0000-0002-8573-8009
Hicks, Debbie
-
Funding
Funding for this research was provided by:
Cancer Research UK (CRUK/23391)
Children's Cancer North
- License Information
-
More Information
Article History
Received: 18 January 2023
Revised: 17 March 2023
Accepted: 17 March 2023
First Online: 4 April 2023
Declarations
:
: Tumour samples assembled from UK-CCLG institutions were provided as part of the CCLG approved biological study BS-2007-04. Human tumour investigations were conducted with approval from Newcastle/North Tyneside Research Ethics Committee (study reference 07/Q0905/71). Informed consent was obtained for all patients.
: S.M.P. reports grants or contracts from ITCC-P4 companies; Lilly, Roche, Pfizer, Charles River, Bayer HealthCare, Pharma Mar, Amgen, Sanofi, Astra Zeneca and Servier. S.Ru. reports participation on advisory boards for Bayer (Germany), Roche (Germany), BMS (Germany) and data safety monitoring board for Cellgene (USA). All other authors declare no competing interests.
